PharmaMar is Present at the 16th International Gynecologic Cancer Society Meeting With New Evidence on Yondelis®

MADRID, October 31, 2016 /PRNewswire/ --

PharmaMar (MCE:PHM) presents the new data obtained from several clinical studies carried out with its antitumor compound of marine origin, Yondelis^®, during the 16^th Biennial International Gynecologic Cancer Society Meeting (IGCS) that is taking place in Lisbon, Portugal, from the 29^th to the 31^st of October.

     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

Through several presentations, PharmaMar is highlighting the role of trabectedin in platinum-sensitive ovarian cancer patients. It has been presented an overall survival analysis of the patients with relapsed ovarian cancer treated with platinum, compared to non-platinum treatments after receiving trabectedin in combination with pegylated liposomal doxorrubicin (PLD) or PLD as a single agent; as well as a Phase II clinical trial that suggests that trabectedin in combination with bevacizumab may provide a promising regimen in patients that are partially sensitive to platinum in relapsed ovarian cancer.      

Apart from presenting clinical data results, PharmaMar presents a cost-comparison study on trabectedin plus PLD -at first relapse- followed by platinum based chemotherapy in comparison to bevacizumab-based maintenance schema in first line patients with a high risk of ovarian cancer. As a principal conclusion, it can be observed that the survival rate achieved by both is tantamount, although the cost of the trabectedin regimen is lower.    

To finish with, PharmaMar has organized a satellite symposium entitled 'Managing relapsed ovarian cancer in a rapidly evolving landscape' in which international experts will analyze, amongst other subjects, at which moment it is convenient to use platinum; the role of trabectedin + PLD when it is not convenient to treat patients with a new treatment with platinum; and the treatments of ovarian cancer taking into account the 2015 Tokyo International Consensus of the Gynecological Cancer Intergroup and daily clinical practice.

Main studies that PharmaMar presents at IGCS 2016  

• OS analysis by treatments received after trabectedin/PLD or PLD alone in patients with recurrent ovarian cancer: Platinum vs. non-platinum (OVA-301)  

e-poster. Lead author: Andrés Poveda, MD, et al. Valencia Institute of Oncology, Spain  

• Randomized, non-comparative, phase II trial of bevacizumab and trabectedin with or whitout carboplatin in platinum partially-sensitive recurring ovarian cancer women (IRFMN-OVA-6152 study)  

Oral session e-poster. Lead author: Prof. Nicoletta Colombo, PhD, et al. Instituto Europeo de Oncología, Milan, Italy

• Audit of trabectedin use in high grade serous carcinoma 

e-poster. Lead author: S. Thair, MD, et al. Broomfield Hospital, Oncology, Chelmsford, United Kingdom

• Trabectedin in heavily pretreated recurrent ovarian cancer patients: a case-control study  

e-poster. Lead author: Prof. P. Benedetti Panici, et al, Policlinico Umberto I - Sapienza University of Rome, Italy

• Trabectedin plus pegylated liposomal doxirubicin -at first relapse- followed by platinum based chemotherapy versus bevacizumab-based maintenance schema in first line, high-risk ovarian cancer patients: a cost-comparison study  

e-poster. Lead authors: J.M. Fernández Santos, PharmaMar, Colmenar Viejo, Madrid; J.M. del Campo, Diagonal clinic, Barcelona, Spain  

Media Relations: Paula Fernández, +34-638-79-62-15 and Investor Relations, +34-914444500